Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.70 |
| ▸ | CCND1 | P24385 | 4/20 | 0.70 |
| ▸ | CCND2 | P30279 | 4/20 | 0.70 |
| ▸ | CCND3 | P30281 | 4/20 | 0.70 |
| ▸ | PTK2 | Q05397 | 16/20 | 0.55 |
| ▸ | JAK2 | O60674 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | PAK4 | O96013 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808266 | 0.92 | CDK4 (0.58) | CDK4CCND1CCND2CCND3PTK2 | |
| SCHEMBL6808118 | 0.90 | CDK4 (0.66) | CDK4CCND1CCND2CCND3PTK2 | |
| SCHEMBL6809354 | 0.90 | CDK4 (0.72) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL6812506 | 0.85 | CDK4 (0.76) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL6807764 | 0.85 | CDK4 (0.66) | CDK4CCND1CCND2CCND3JAK2 | |
| SCHEMBL6809040 | 0.84 | CDK4 (0.80) | CDK4CCND1CCND2CCND3PTK2 | |
| SCHEMBL6812200 | 0.84 | CDK4 (0.74) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL6807191 | 0.83 | CDK4 (0.72) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL5264058 | 0.82 | CDK4 (1.00) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL6811976 | 0.82 | PTK2 (0.64) | CDK4CCND1CCND2CCND3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | claimed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | CDK4 1/4885CCND1 23/4885CCND2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.